Diffuse large B-cell lymphoma refractory
Not recruitingStudy on the Safety and Effectiveness of Polatuzumab Vedotin with Rituximab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Study on the Safety and Effectiveness of Polatuzumab Vedotin with Rituximab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Disease:Diffuse large B-cell lymphoma refractory
- Substances:OxaliplatinPolatuzumab Vedotin+2
Greece- Participants:18–64 years · 65+ years
- Substances:Oxaliplatin
- Sponsor:F. Hoffmann-La Roche AG













